Literature DB >> 28290392

Potential for differentiation of glioma recurrence from radionecrosis using integrated 18F-fluoroethyl-L-tyrosine (FET) positron emission tomography/magnetic resonance imaging: A prospective evaluation.

Shanti K Sogani1, Amarnath Jena2, Sangeeta Taneja2, Aashish Gambhir2, Anil K Mishra3, Maria M D'Souza3, Sapna M Verma4, Puja P Hazari3, Pradeep Negi2, Ganesh K R Jadhav4.   

Abstract

PURPOSE: To assess the utility of 18F-fluoroethyl-L-tyrosine (FET) positron emission tomography/magnetic resonance imaging (PET/MRI) in distinguishing recurrence from radionecrosis.
MATERIALS AND METHODS: Thirty-two patients (25 males, 7 females) of glioma who had already undergone surgery/chemoradiotherapy and had enhancing brain lesions suspicious of recurrence were evaluated using integrated 18F-FET PET/MRI, and followed up with histopathology or clinical follow-up and/or MRI/PET/MRI imaging. Manually drawn regions of interest over areas of maximal enhancement or FET uptake were used to calculate tumor to background ratios [TBRmax, TBRmean], choline: creatine ratio [Cho: Cr ratio], normalized relative cerebral blood volume [N rCBVmean] and apparent diffusion coefficient [ADCmean]. Correlations were evaluated using Pearson's coefficient. Accuracy of each parameter was calculated using independent t-test and receiver operator curve (ROC) analysis while utility of all four parameters together using multivariate analysis of variance (MANOVA) for differentiating recurrence vs. radionecrosis was evaluated. Positive histopathology and imaging/clinical follow up served as the gold standard.
RESULTS: Twenty-four of the 32 patients were diagnosed with recurrent disease and 8 with radiation necrosis. Significant correlations were observed between TBRmaxand N rCBVmean (ρ =0.503; P = 0.003), TBRmean, and N rCBVmean (ρ =0.414; P = 0.018), TBRmaxand ADCmean (ρ = -0.52; P = 0.002), and TBRmeanand ADCmean(ρ = -0.518; P = 0.002). TBRmax, TBRmean, ADCmean, Cho: Cr ratios, and N rCBVmeanwere significant in differentiating recurrence from radiation necrosis with an accuracy of 94.1%, 88.2%, 80.4%, 96.4%, and 89.9%, respectively. MANOVA indicated that combination of all parameters demonstrated better evaluation of recurrence vs. necrosis than any single parameter. The diagnostic accuracy, sensitivity, and specificity using all MRI parameters were 93.75%, 96%, and 85.7%, and using all FET PET/MRI parameters was 96.87%, 100%, and 85.7%, respectively.
CONCLUSIONS: Synergetic effect of multiple MR parameters evaluated together in addition to FET PET uptake highlights the fact that integrated 18F-FET PET/MRI might have the potential to impact management of patients with glioma by timely and conclusive recognition of true recurrence from radiation necrosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28290392     DOI: 10.4103/neuroindia.NI_101_16

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  11 in total

1.  Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.

Authors:  Derek Richard Johnson; Chad Allan Glenn; Ramin Javan; Jeffrey James Olson
Journal:  J Neurooncol       Date:  2021-10-25       Impact factor: 4.130

2.  Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [18F]FET PET in patients with suspected recurrent anaplastic astrocytoma and glioblastoma.

Authors:  Otto M Henriksen; Adam E Hansen; Aida Muhic; Lisbeth Marner; Karine Madsen; Søren Møller; Benedikte Hasselbalch; Michael J Lundemann; David Scheie; Jane Skjøth-Rasmussen; Hans S Poulsen; Vibeke A Larsen; Henrik B W Larsson; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-07-30       Impact factor: 10.057

Review 3.  The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI.

Authors:  Giulia Santo; Riccardo Laudicella; Flavia Linguanti; Anna Giulia Nappi; Elisabetta Abenavoli; Vittoria Vergura; Giuseppe Rubini; Roberto Sciagrà; Gaspare Arnone; Orazio Schillaci; Fabio Minutoli; Sergio Baldari; Natale Quartuccio; Sotirios Bisdas
Journal:  Diagnostics (Basel)       Date:  2022-03-29

Review 4.  Diagnostic Performance of PET and Perfusion-Weighted Imaging in Differentiating Tumor Recurrence or Progression from Radiation Necrosis in Posttreatment Gliomas: A Review of Literature.

Authors:  N Soni; M Ora; N Mohindra; Y Menda; G Bathla
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-27       Impact factor: 3.825

5.  Individualized discrimination of tumor recurrence from radiation necrosis in glioma patients using an integrated radiomics-based model.

Authors:  Kai Wang; Zhen Qiao; Xiaobin Zhao; Xiaotong Li; Xin Wang; Tingfan Wu; Zhongwei Chen; Di Fan; Qian Chen; Lin Ai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-26       Impact factor: 9.236

Review 6.  Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors.

Authors:  Wynton B Overcast; Korbin M Davis; Chang Y Ho; Gary D Hutchins; Mark A Green; Brian D Graner; Michael C Veronesi
Journal:  Curr Oncol Rep       Date:  2021-02-18       Impact factor: 5.075

7.  Diagnostic and Prognostic Potential of 18F-FET PET in the Differential Diagnosis of Glioma Recurrence and Treatment-Induced Changes After Chemoradiation Therapy.

Authors:  Monica Celli; Paola Caroli; Elena Amadori; Donatella Arpa; Lorena Gurrieri; Giulia Ghigi; Patrizia Cenni; Giovanni Paganelli; Federica Matteucci
Journal:  Front Oncol       Date:  2021-10-04       Impact factor: 6.244

Review 8.  High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 2: Spectroscopy, Chemical Exchange Saturation, Multiparametric Imaging, and Radiomics.

Authors:  Thomas C Booth; Evita C Wiegers; Esther A H Warnert; Kathleen M Schmainda; Frank Riemer; Ruben E Nechifor; Vera C Keil; Gilbert Hangel; Patrícia Figueiredo; Maria Del Mar Álvarez-Torres; Otto M Henriksen
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 5.738

9.  [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis.

Authors:  Thuy T Tran; Jean-Dominique Gallezot; Lucia B Jilaveanu; Christopher Zito; Gabriela Turcu; Keunpoong Lim; Nabeel Nabulsi; Henry Huang; Anita Huttner; Harriet M Kluger; Veronica L Chiang; Richard Carson
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

10.  Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis.

Authors:  Meng Cui; Rocío Isabel Zorrilla-Veloz; Jian Hu; Bing Guan; Xiaodong Ma
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.